Combivir (AZT/3TC): Research

Switching From Zidovudine/Lamivudine to Tenofovir/Emtricitabine: Results of an Uncontrolled Cohort (November 16, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
On TheBodyPRO.com
Zidovudine/Lamivudine Inferior as First-Line NRTI Backbone (August 15, 2006)
In XVI International AIDS Conference
On TheBodyPRO.com
In Head-to-Head International Study, Tenofovir + Emtricitabine Bests Zidovudine/Lamivudine in Tolerability and Convenience (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
On TheBodyPRO.com
No K65R Mutations in Patients Failing Tenofovir + Emtricitabine (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
On TheBodyPRO.com
Incidence of Zidovudine-Associated Anemia May Be Lower Than Initially Thought -- Particularly With Fixed-Dose Combinations (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
Aurobindo Receives Tentative FDA Approval to Produce Generic Version of Combivir for PEPFAR (July 11, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Aurobindo Pharma Receives Tentative FDA Approval to Produce Generic Stavudine for PEPFAR (July 5, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Addition of Short-Course Zidovudine/Lamivudine to Single-Dose Nevirapine Decreases Development of Maternal NNRTI-Resistant HIV (July 15, 2004)
In The XV International AIDS Conference, from TheBodyPRO.com
U.S. Approves Emtriva; Gilead Hopes Viread/Emtriva Combo Will Compete With Combivir (July 3, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Trizivir-Only Arm Closed in PI-Sparing, Naive Therapy Trial (March 10, 2003)
Important interim results from a Phase III, randomized, double-blind comparison of three protease-inhibitor-sparing regimens for the initial treatment of HIV infection (AACTG Protocol A5095).
To read PDF, click here.
From U.S. National Institute of Allergy and Infectious Diseases
On TheBodyPRO.com
Adherence to Combivir as Post-Exposure Prophylaxis in Non-Occupational HIV Exposures (July 8, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
Prospective Study of Hyperlipidemia in ART-Naive Subjects Taking Combivir/Abacavir/Nelfinavir, or Stavudine/Lamivudine/NFV (ESS40002) (February 25, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
The Compact Quad, Combivir/Abacavir/Efavirenz -- Preliminary 48-Week Results (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from TheBodyPRO.com
Abacavir/Combivir Is Comparable to Indinavir/Combivir in HIV-1 Infected Antiretroviral Therapy Naive Adults: Preliminary Results of a 48-Week Open-Label Study (CNA3014) (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
Metabolic and Anthropometric Changes Observed in HIV-Infected Patients Treated With Combivir (ZDV/3TC) Plus Nelfinavir or Nevirapine (A Substudy of the COMBINE Study) (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
A Randomized Open Label Study to Investigate Abacavir and Lamivudine as Once-Daily Components of a Triple-Combination Regimen (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
Final 12-Month Results From the COMBINE Study: A Randomized, Open, Multicenter Trial Comparing Combivir Plus Nelfinavir or Nevirapine in Naive Patients (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
The PI-Sparing Compact Quad Regimen of Combivir (COM)/Abacavir (ABC)/Efavirenz (EFV) Is Potent and Well-Tolerated in Antiretroviral Therapy (ART) Naive Subjects With High Viral Loads: 24-Wk Data (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
Comparison of a Triple Combination Regimen Containing an Enteric-Coated Formulation of Didanosine Administered Once Daily Versus a Regimen of Combivir Plus Nelfinavir (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Efficacy of Combivir (COM) (Lamivudine 150 mg/Zidovudine 300 mg) Plus Ziagen (Abacavir (ABC) 300 mg) BID Compared to Trizivir (TZV) (3TC 150 mg/ZDV 300 mg/ABC 300 mg) BID in Patients Receiving Prior COM Plus ABC (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Time to Appearance of NRTI-Associated Mutations and Response to Subsequent Therapy for Patients on Failing ABC/COM (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com

1 | 2 Next >